8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 9, 2026·SEC
Invivyd, Inc.(IVVD)Earnings, Financials & Key Ratios
IVVD•NASDAQ
$0.89
Price updated Jun 27, 2026
AboutAdagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.Show more
- Revenue$53M+110.5%
- EBITDA-$53M+69.2%
- Net Income-$52M+69.1%
- EPS (Diluted)-0.30+79.0%
- Gross Margin92.99%-0.7%
- EBITDA Margin-100.05%+85.4%
- Operating Margin-103.99%+85.1%
- Net Margin-98.25%+85.3%
- ROE-33.96%+75.5%
IVVD Price & Volume
Invivyd, Inc. (IVVD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Antibody Platform Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Rapid viral mutation obsolescence
"Invivyd faces a precarious outlook as its single-asset COVID-19 therapeutic portfolio remains highly susceptible to rapid viral mutation and product obsolescence. While the company maintains gross margins consistently exceeding 90%, the massive R&D burden—which peaked at $62.3M in 2023Q4—continues to drive significant operating losses. Investors should remain cautious as the firm's reliance on lumpy, non-recurring revenue cycles and a narrowing cash runway of $184.2M as of 2026Q1 suggest a high probability of future capital dilution."
Verdict Logic
the company's reliance on a single-product model and its rapid cash depletion, evidenced by a decline in cash from $226.7M in 2025Q4 to $184.2M in 2026Q1, present excessive risk for long-term investors.
IVVD Growth Metrics
Invivyd, Inc. (IVVD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM52.27%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM45.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM68.81%
Return on Capital
10 Years-81.44%
5 Years-76.25%
3 Years-86.2%
Last Year-35.82%
IVVD Recent Earnings
Invivyd, Inc. (IVVD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.13-62.5%
$0.08
Rev
$14M-23.8%
$18M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.02+133.3%
$0.06
Rev
$17M+0.0%
$17M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.06-20.0%
$0.05
Rev
$13M-15.4%
$16M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.12-200.0%
$0.04
Rev
$12M-59.4%
$29M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.13vs $0.08-62.5% | $14Mvs $18M-23.8% |
| Q2 2026 | Mar 5, 2026 | $0.02vs $0.06+133.3% | $17Mvs $17M+0.0% |
| Q4 2025 | Nov 6, 2025 | $0.06vs $0.05-20.0% | $13Mvs $16M-15.4% |
| Q3 2025 | Aug 14, 2025 | $0.12vs $0.04-200.0% | $12Mvs $29M-59.4% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Invivyd, Inc. (IVVD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.89 | $118.35M | -2.97 | 110.47% | -98.25% | -33.96% | — | |
| $632.90 | $65.76B | 15.26 | 0.99% | 29.65% | 14.32% | — | |
| $491.34 | $124.98B | 32.07 | 9.57% | 35.4% | 23.93% | — | |
| $4.14 | $1.28B | 207.00 | 22.23% | -6.63% | — | — | |
| $8.75 | $2.03B | 14.58 | 19.63% | 32.43% | 38.97% | — | |
| $3.80 | $203.52M | -4.81 | -100% | — | -0.29% | — |
Compare IVVD vs Peers
Invivyd, Inc. (IVVD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IVVD SEC Filings & Documents
Invivyd, Inc. (IVVD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IVVD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IVVD Frequently Asked Questions
Invivyd, Inc. (IVVD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Invivyd, Inc.'s revenue?
Invivyd, Inc. (IVVD) reported $55.9M in revenue for fiscal year 2025.
How fast is Invivyd, Inc. growing?
Invivyd, Inc. (IVVD) grew revenue by 110.5% over the past year. This is strong growth.
Is IVVD profitable?
Invivyd, Inc. (IVVD) reported a net loss of $77.6M for fiscal year 2025.
Dividend & Returns
What is IVVD's return on equity?
Invivyd, Inc. (IVVD) has a return on equity (ROE) of -34.0%. Negative ROE indicates the company is unprofitable.
What is Invivyd, Inc.'s free cash flow?
Invivyd, Inc. (IVVD) had negative free cash flow of $79.5M in fiscal year 2025, likely due to heavy capital investments.